INTRODUCTION
Angiogenesis, the process by which new blood vessels are formed from preexisting ones, plays an essential role in tumor growth, invasion, and metastasis (1) . Angiogenesis is predominantly regulated by vascular endothelial growth factor (VEGF), which binds to the tyrosine kinase receptor VEGFR2, inducing the dimerization and phosphorylation of the receptor (2) (3) (4) (5) (6) . VEGFR2 is phosphorylated at several intracellular phosphorylation sites (including tyrosine residues 951, 1054, 1059, 1175, and 1214) (7) (8) (9) , but the phosphorylation of Tyr 1175 is required for angiogenic functions (5, (10) (11) (12) (13) . Different VEGFR2 phosphorylation events induce distinct signaling pathways such as mitogen-activated protein kinases (12) , phosphatidylinositol 3-kinase/AKT (14) , and nitric oxide production (15) , resulting in the regulation of proliferation, survival, migration, and vascular permeability of endothelial cells. Upon activation by the binding of specific ligands, growth factor receptors are internalized, which can lead to receptor degradation and the termination of signaling (16) . However, internalized VEGFR2 continues to signal from the endosomal compartments in endothelial cells (17) .
The urokinase plasminogen activator receptor (uPAR; also known as CD87) also contributes to angiogenesis (18, 19) . uPAR is a glycosylphosphatidylinositolanchored protein (20) that contains three homologous domains, designated as D1, D2, and D3, which are connected by short linkers (21) . At the cell surface, uPAR is the receptor for the inactive precursor pro-urokinase (pro-uPA) (22) . VEGF can induce endothelial cell migration by activating pro-uPA bound to uPAR (23) , which requires the internalization and redistribution of uPAR and integrins (24, 25) . Because uPAR lacks transmembrane and cytosolic domains, it must interact with other partners such as vitronectin (26) , caveolin (27) , the G protein (heterotrimeric guanine nucleotidebinding protein)-coupled receptor FPLR1 (28) , various receptor tyrosine kinases, including epidermal growth factor receptor (EGFR) (29, 30) and platelet-derived growth factor receptor (PDGFR) (31) , integrins (32) (33) (34) (35) (36) , and low-density lipoprotein receptor-related protein 1 (LRP-1) (37) (38) (39) to transduce signaling and to modulate angiogenic effects (33, (40) (41) (42) .
One way in which angiogenesis is tightly regulated is through the interaction of VEGFR2 with its co-receptors (43) (44) (45) (46) . We show here that VEGF induced the formation of a complex between VEGFR2, b 1 integrin, uPAR, and LRP-1 at the cell surface of endothelial cells. We also demonstrate that LRP-1-dependent internalization of this complex upon VEGF stimulation is crucial for VEGFR2 signaling and its biological effects.
RESULTS

VEGF induces the interaction of VEGFR2 with uPAR
Previous studies have reported that uPAR participates in the VEGF-induced migration of endothelial cells (24, 25) . To determine the mechanism by which uPAR regulates VEGF signaling, we performed proximity ligation assays (PLAs) to determine whether VEGFR2 forms a complex with uPAR on the cell membrane in human umbilical vein endothelial cells (HUVECs) after VEGF stimulation. The red dots in the PLA images indicate that uPAR and VEGFR2 were located less than 40 nm from each other after 10 min of VEGF stimulation (Fig. 1A) . To confirm that VEGFR2 formed a complex with uPAR, we performed coimmunoprecipitation experiments. In HUVECs, the association of VEGFR2 with uPAR was enhanced upon VEGF treatment (Fig. 1B) . We wondered whether VEGFR2 also interacted with other binding partners of uPAR, such as LRP-1 and integrins (34, 38, 47, 48) . PLAs indicated that within 10 min of stimulation with VEGF, VEGFR2 formed complexes with b 1 integrin and LRP-1 complexes (Fig. 1A) . Coimmunoprecipitation analysis confirmed that VEGF stimulation induced an increase in the amount of VEGFR2 or uPAR that associated with b 1 integrin, which was not due to increases in the overall abundance of VEGFR2, uPAR, or b 1 integrin as assessed by immunoblotting of cell lysates (Fig. 1, B to D) . Previous studies have reported that b 3 integrin binds to VEGFR2 (49) (50) (51) (52) . However, in our study, VEGF treatment did not induce the formation of a VEGFR2/b 3 integrin complex (Fig. 1A) . Consistent with these results, PLAs revealed that VEGF induced the formation of uPAR/b 1 integrin and uPAR/LRP-1 complexes, but not of an uPAR/b 3 integrin complex (Fig. 1E) . Together, these data indicate that uPAR, b 1 integrin, and LRP-1 interact with VEGFR2 upon VEGF treatment.
uPAR promotes VEGFR2 signal transduction and its biological effects on endothelial cells in vitro and neovascularization in vivo
We next investigated how uPAR affects VEGF-induced angiogenesis. Transfection of HUVECs with an uPAR small interfering RNA (siRNA) duplex reduced uPAR protein abundance by 50% ( Fig. 2A) .To analyze whether VEGF-induced endothelial cell migration requires uPAR, wound closure assays in HUVECs were performed, which showed that uPAR knockdown abolished VEGF-induced migration (Fig. 2B ). In addition, we evaluated whether uPAR is essential for VEGF-induced proliferation by measuring BrdU (5-bromo-2′-deoxyuridine) incorporation. The proliferation induced by VEGF was significantly reduced in uPAR-knockdown HUVECs compared to HUVECs transfected with control siRNA (Fig.  2C) . Because VEGF increases vascular permeability (15, 53), we and analyzed by Western blotting using rabbit anti-uPAR antibody, a rabbit anti-b 1 integrin antibody, and a rabbit anti-VEGFR2 antibody. Right panels show cell lysates before immunoprecipitation. *P < 0.05. (E) PLAs for uPAR and LRP-1, b 1 integrin, or b 3 integrin were performed as described in (A). PLA: images show representative experiment; graphs are mean and SE (n = 4 to 10 images, two independent experiments). IP: images show representative experiment; graphs are mean and SE (n = 3 immunoprecipitation experiments except for IP: uPAR, WB: VEGFR2, n = 5 immunoprecipitation experiments). **P < 0.01; ***P < 0.001; ns, not significant. examined the influence of uPAR on VEGF-induced permeability and found that transfection of uPAR siRNA decreased the ability of VEGF to induce permeability in HUVECs (Fig. 2D) . Effects on migration and proliferation were confirmed using a second siRNA for uPAR ( fig. S1 , A and B). As a second strategy to inhibit uPAR, we used blocking antibodies designed against the D1 or D2 domain of uPAR. Although preincubation of HUVEC with either U1 or U2 antibody alone did not alter HUVEC migration, the combination of both resulted in reduced VEGF-induced migration (fig. S1, C to E). These results suggest that blocking both domains is required to prevent VEGFR2 function.
To further determine whether uPAR silencing also affects neovascularization in vivo, we investigated the role of uPAR in the angiogenic effects of VEGF in the retinal vasculature of uPAR −/− and wild-type mice. The retina is avascular at birth, and a layer of blood vessels grows from the optic nerve toward the periphery from postnatal day 1 until postnatal day 7 (54) . During the extension of the developing superficial vascular plexus (Fig.  2E) , the retinal surface was colonized by vessels, and the complexity, which is characterized by the number of branch points in the vascular network, was significantly increased in wild-type newborn pups that were intraocularly injected with recombinant VEGF compared to pups injected with vehicle.
This increase was abrogated in uPAR −/− pups that were injected with VEGF (Fig.  2, F (Fig. 2I) . These data suggest that uPAR enables VEGFR2 to mediate its angiogenic effects in vitro and in vivo.
We next examined the effects of uPAR silencing on VEGF signaling. In HUVECs with uPAR knockdown, the phosphorylation of VEGFR2 at Tyr 1175 after VEGF stimulation was decreased by 40% compared to control cells (si-Ctrl). uPAR knockdown also decreased the downstream induction of extracellular signal-regulated kinase (ERK) phosphorylation by VEGF, (45%), but not that of AKT phosphorylation (Fig. 3A) . These results suggest that uPAR is a binding partner of VEGFR2.
VEGF induces the internalization of VEGFR2, uPAR, b 1 integrin, and LRP-1 in endothelial cells
Because internalization of VEGFR2 is crucial for its signaling, we analyzed the impact of uPAR on the VEGFR2 internalization process. VEGFR2 interacted with LRP-1 ( Fig. 1) , a protein that is involved in uPAR internalization (39, 56) ; therefore, we determined whether VEGFR2, uPAR, b 1 integrin, and LRP-1 were internalized after short-term VEGF treatment. Flow cytometry analysis on nonpermeabilized HUVECs indicated that 15 min of stimulation with VEGF decreased the surface abundance of VEGFR2 (33%), uPAR (47%), b 1 integrin (38%), and LRP-1 (13%) (Fig. 3 , B to E). As expected, b 3 integrin, which was not detected in this complex (Fig. 1A) , did not show differences in cell surface abundance after VEGF stimulation (Fig. 3F ). To determine whether these decreases reflected the internalization of these proteins, we performed biotinylation experiments. HUVECs were surfacebiotinylated and then subjected to VEGF treatment for 10 min. Biotin attached to the proteins remaining at the cell surface was selectively cleaved using a membrane-impermeable reducing agent, and internalized biotinylated pool was detected using labeled streptavidin. Fifteen minutes of treatment with VEGF induced the internalization of VEGFR2, uPAR, and b 1 integrin (Fig. 3G) . Together, these data suggest that VEGF induces the internalization of the components of the VEGFR2/uPAR/ b 1 integrin/LRP-1 complex.
VEGF requires internalization mediated by LRP-1 for its effects on endothelial cells
We next investigated whether VEGF requires internalization of the VEGFR2/uPAR/b 1 integrin/LRP-1 complex to mediate its angiogenic effects. To that aim, we incubated HUVECs with dynasore to block dynamin-dependent endocytosis (57) before VEGF treatment. VEGFmediated phosphorylation of VEGFR2 and ERK, but not that of AKT, was reduced after dynasore preincubation compared to control cells (Fig. 4A) . The presence of LRP-1 in the complex led us to postulate that the internalization mediated by VEGF was LRP-1-dependent. To verify this hypothesis, we incubated HUVECs with receptor-associated protein (RAP), an LRP-1 antagonist that inhibits LRP-1-dependent internalization, before VEGF stimulation (56) . The ability of VEGF to induce migration and proliferation was reduced in the presence of RAP compared to control HUVECs (Fig. 4 , B and C). The permeability induced by VEGF was also significantly reduced in HUVECs pretreated with RAP (Fig. 4D) . We next analyzed whether LRP-1 deficiency affects VEGF signaling. In control HUVECs, VEGF-mediated phosphorylation of VEGFR2 and ERK, but not that of AKT, were decreased in the presence of RAP compared to untreated control cells (Fig. 4E) . Together, these data suggest that VEGF requires LRP-1-dependent internalization to mediate its angiogenic effects.
uPAR is required for VEGFR2 internalization
Our previous observations showed that uPAR enables VEGF to induce its effects. Moreover, we showed that VEGFR2 requires internalization that is mediated by LRP-1 to exert its angiogenic effects. Because LRP-1 interacts with uPAR, we performed PLAs to test our hypothesis that uPAR was the principal mediator of VEGFR2 internalization. HUVECs with uPAR knockdown contained lower amounts of the VEGFR2/LRP-1 complex after VEGF treatment, suggesting a role for uPAR in the induction of the interaction of VEGFR2 with LRP-1. In addition, cell surface biotinylation assays showed that VEGFR2 and b 1 integrin internalization in response to VEGF was reduced in HUVECs transfected with uPAR siRNA compared to those transfected with control siRNA (Fig. 4G) . or uPAR siRNA were stimulated with VEGF. The phosphorylation of VEGFR2, ERK1/2, and AKT was measured by Western blotting, and total VEGFR2, ERK1/2, AKT, and tubulin were used as internal controls. uPAR abundance was used as a transfection control. Images show one representative experiment; graphs are mean and SE from three independent experiments. *P < 0.05; **P < 0.01; ns, not significant. (B to F) Cell surface abundance of VEGFR2 (B), uPAR (C), b 1 integrin (D), LRP-1 (E), and b 3 integrin (F) in nonpermeabilized HUVECs incubated in the absence (black) or presence of VEGF (red) was determined by flow cytometry. Secondary antibody alone (sec Ab, gray) was used as an internal control. The graph summarizes the quantitative analysis of the cell surface protein abundance, which was calculated from the geometric mean of the fluorescence intensities from three separate experiments. Images show one representative experiment; graphs are mean and SE from all experiments. **P < 0.01; ***P < 0.001; ns, not significant. (G) Internalization of VEGFR2, b 1 integrin, and uPAR measured after cell surface biotinylation. Biotinylated proteins were recovered by affinity precipitation on streptavidin beads, subjected to Western blot analysis, and quantified by densitometry relative to the unstimulated control. Tubulin in cell lysates was used as an internal control. Images show one representative experiment of two independent experiments.
These differences in internalization were not due to changes in the abundance of VEGFR2 and b 1 integrin (Fig. 4B) .
DISCUSSION
Our results demonstrate that VEGFR2, a major mediator of angiogenic signaling, interacts with uPAR at the cell surface. Silencing of uPAR disrupted VEGFR2 signaling downstream of VEGFR2, leading to impaired angiogenesis in vivo. After uPAR binding, VEGFR2 was internalized in the cell in an LRP-1-dependent manner. VEGFR2 signaling is the consequence of several steps that are initiated at the cell surface upon ligand binding. VEGF binding to VEGFR2 leads to the recruitment of co-receptors that might modulate downstream signaling and angiogenic functions. For example, after VEGF stimulation, NRP-1 recruits the synectin-myosin VI complex to VEGFR2 to induce its internalization, which perpetuates the signals involved in survival, migration, and permeability. Another VEGFR2 binding partner, ephrin B2, regulates tip cell filopodia extension by inducing VEGFR2 internalization (44, 46) . Moreover, we found that uPAR enhanced the ability of VEGF to induce migration, proliferation, and permeability of endothelial cells and angiogenesis in vivo.
We showed that uPAR was required for VEGFR2 signaling and function in vitro. In vivo, the effect in uPAR −/− mice was less impressive, although statistically significant. Such a discrepancy has been previously described (40) . The strongest effect observed in vitro 72677 was unlikely due to our siRNA silencing methodology because endothelial cells isolated from uPAR −/− mice showed similar reductions in proliferative and migratory capacities (18) . It had been thought that the uPAR −/− mice do not have physiological abnormalities because they appeared normal and were fertile (58) . Indeed, our results did not show any difference in the neovascularization of the retinas of uPAR −/− and wild-type mice without VEGF administration. A similar lack of effect was observed in untreated Matrigels. Consistent with our findings, Matrigel data obtained by Larusch and collaborators showed that uPAR depletion affected angiogenesis in response to VEGF stimulation, but not in the absence of VEGF (29) . Thus, in general, uPAR −/− mice do not show a strong angiogenic phenotype. However, uPAR −/− mice show severe reductions in microvessel density in the myocardium (59) and in the dermis (60) . Those observations suggest that, depending on the microenvironment, the impact of the absence of uPAR on vascularization could be more pronounced. The in vitro phenotype of uPAR −/− endothelial cells also argues for compensatory mechanisms that are microenvironment-dependent. One explanation could be that urokinase-type plasminogen activator (uPA) compensates the lack of uPAR by activating other signaling pathways, and indeed, uPA by its kringle domain interacts specifically with a v b 3 integrin in uPAR-depleted CHO (Chinese hamster ovary) cells (61) and the isolated uPA kringle domain binds other integrins such as a 4 b 1 and a 9 b 1 (62) . Nevertheless, the precise role of uPAR in modulating vascularization in vivo warrants further investigation. uPAR silencing affected VEGFR2 signaling by reducing the phosphorylation of VEGFR2 at Tyr 1175 , one of the first steps in VEGFR2 signaling. ERK phosphorylation induced by VEGF was also affected in the uPAR-deficient cells. These data agree with a previous study showing that the phosphorylation of VEGFR2 at Tyr 1175 is crucial for the binding and activation of phospholipase C-g, which is a major effector of ERK activation (12) . These data show that uPAR is a binding partner of VEGFR2.
Our results also showed that b 1 integrin is recruited to the VEGFR2/ uPAR complex at the cell surface. b 1 integrin interacts with the D2 and D3 domains of uPAR (34, 47, 48) and also binds VEGFR2 (43) . We therefore suggest that b 1 integrin acts as an adaptor protein between uPAR and VEGFR2. A similar model has been proposed for the interaction between b 1 integrin, uPAR, and another tyrosine kinase receptor, EGFR, in endothelial and cancer cells (29, 30, 63) .
The recruitment of b 1 integrin and uPAR to VEGFR2 is likely to occur in lipid raft microdomain at the cell membrane. Various studies have shown that VEGFR2 colocalizes with caveolin-1 in lipid rafts and have suggested that VEGFR2 localization to lipid rafts is necessary for VEGFR2 dimerization and endocytosis and endothelial cell migration and proliferation (64) (65) (66) (67) (68) (69) . In addition, activation of both b 1 integrin (70) and uPAR (71) requires recruitment to lipid rafts.
Currently, the internalization of VEGFR2 is considered to be an important mechanism by which cells control the intensity and duration of downstream signaling. An important question that is raised by our results is how uPAR mediates VEGFR2 internalization. Our data showed that VEGF stimulation led to the recruitment of LRP-1 in the VEGFR2/b 1 integrin/uPAR complex at the endothelial cell surface. By interacting with the D3 domain of uPAR, LRP-1 can also induce the internalization of uPAR-associated proteins, such as integrins, its ligand uPA, and its inhibitor plasminogen activatory inhibitory type 1 (PAI-1) (38, 56, 72) . Using flow cytometry and cell surface biotinylation assays, we demonstrated that all members of this complex were internalized after short-term VEGF treatment.
To date, no binding sites for LRP-1 have been described on VEGFR2. Because LRP-1 is required for uPAR internalization (56, 72) , we speculate that uPAR brings LRP-1 into the complex, subsequently leading to VEGFR2 internalization. Supporting this hypothesis is the observation that under some conditions (for example, when bound to PAI-1 and uPA), uPAR can interact with LRP-1 on the plasma membrane through its D3 domain (38) . On the basis of these observations, we suggest that PAI-1 and uPA may also be members of the VEGFR2 complex at the cell surface.
Then, we wondered whether VEGFR2 internalization mediated by LRP-1 was required for VEGFR2 signal transduction and its biological effects on endothelial cells. We found that RAP, an inhibitor of LRP-1-dependent internalization, impaired VEGF-mediated phosphorylation of VEGFR2 at Tyr 1175 , activation of the VEGFR2 downstream effector ERK (but not that of AKT), and angiogenesis in HUVECs. Together, these data reinforce that internalization is crucial for the angiogenic role of VEGF. Although some initial studies support the view that internalization is a crucial step for signal termination, recent studies favor the role of VEGFR2 internalization in controlling the intensity and duration of the signal. For example, internalized VEGFR2 is not degraded but rather signals from early endosomes (17) . Moreover, VEGFR2 internalization induces signaling and filopodia extension through an ephrin B2-mediated mechanism in endothelial cells from the mouse retina (44) .
In summary, we propose a model in which VEGF induces VEGFR2/ b 1 integrin/uPAR/LRP-1 complex formation at the cell surface. We believe that b 1 integrin enables the association between VEGFR2 and uPAR. In this model, uPAR brings LRP-1 to VEGFR2, and LRP-1 mediates VEGFR2 internalization, thereby promoting signaling by this receptor and angiogenesis (Fig. 5) .
MATERIALS AND METHODS
Cell culture
HUVECs were isolated as previously described (73) . Briefly, umbilical veins were washed with phosphate-buffered saline (PBS), filled with trypsin solution [0.05% trypsin (Difco), 0.2% EDTA, PBS (pH 7.6)], clamped, and incubated in a 37°C water bath for 20 min. Each umbilical vein was washed with PBS, and the eluate was centrifuged to harvest the cells. The HUVECs were seeded into gelatin-coated culture dishes and cultured in EGM-2 medium [EGM-2 BulletKit medium (CC-3162, Lonza) supplemented with 5% fetal bovine serum].
siRNA transfection and internalization inhibitor treatment
For the siRNA experiments, HUVECs were transfected with uPAR or scramble siRNA (50 nM). Assays were performed 72 hours after transfection. For the experiments using internalization inhibitors, the cells were preincubated for 1 hour with RAP (200 nM) (Calbiochem) or dynasore (20 mM) (Sigma) before VEGF treatment. siRNA duplexes were obtained from Integrated DNA Technologies, including two siRNAs targeting uPAR and one negative control. The sequences of the uPAR siRNA (IDT-DNA) were as follows: uPAR siRNA (#1), 5′-GGUGAAGAAGGGCGUCCAA-3′; corresponding control uPAR siRNA, 5′-AACCUGCGGGAAGAA-GUGG-3′. Similar results were obtained with another uPAR siRNA (#2): 5′-CAUUUCCUGUGGCUCAUCA-3′. Cells were transfected using the Ca 3 (PO 4 ) 2 method. Briefly, 2.5 × 10 5 HUVECs were seeded into each well of a six-well plate in serum-free medium (SFM) supplemented with basic fibroblast growth factor (bFGF; 5 ng/ml) and allowed to adhere overnight. siRNA-CaCl 2 complexes were prepared by first combining the siRNA with 10 ml of 2.5 M CaCl 2 . One hundred microliters of HBSP (280 mM NaCl, 1.9 mM Na 2 HPO 4 , 12 mM glucose, 10 mM KCl, 50 mM Hepes, pH 7.05) was added, and the mixture was incubated for 1 min at room temperature. The mixture was added dropwise to the cells, and the cells were incubated for 16 hours. The cells were then collected and seeded for further tests. Antibodies blocking different domains of uPAR were used: domain D1 (U1 antibody; R&D Systems) or D2 of uPAR (U2 antibody; American Diagnostica).
Scratch wound migration assay
In total, 8 × 10 4 cells were seeded into each well of a 48-well plate in 350 ml of SFM (Lonza) with bFGF (5 ng/ml) (Promega) and incubated to reach confluence. Using a pipette tip, a "wound" was made in the monolayer (at time 0). The cells were then washed with PBS and incubated with SFM containing recombinant VEGF (50 ng/ml) (RELIATech GmbH) for 6 hours. In the experiments using internalization inhibitors, the cells were preincubated for 1 hour with RAP (200 nM) (Calbiochem) or dynasore (20 mM) (Sigma) before VEGF treatment. For the siRNA experiments, HUVECs were transfected with uPAR or scramble siRNA (50 nM) using the Ca 3 (PO 4 ) 2 method for 72 hours. After 24 hours of transfection, the HUVECs were seeded in a 48-well plate in SFM containing bFGF (5 ng/ml).
Cell proliferation assay
HUVECs were transfected with siRNA as described above and then trypsinized 24 hours after transfection. A total of 1 × 10 4 cells were seeded into each well of a 96-well plate in 100 ml of SFM (Lonza) containing bFGF (5 ng/ml) (Promega) and incubated for 48 hours. SFM supplemented with recombinant VEGF (50 ng/ml) (RELIATech GmbH) was added to the cells, followed by BrdU 8 hours later, and the culture was incubated for 16 hours. BrdU incorporation was measured with the Cell Proliferation ELISA BrdU (chemiluminescence) kit (Roche Applied Science) according to the manufacturer's protocol.
Permeability assay
Permeability was analyzed in vitro using the diffusion of 75-kD fluorescein isothiocyanate (FITC)-dextran (Sigma) through the endothelial monolayer. A total of 3 × 10 4 cells were seeded in SFM supplemented with bFGF (5 ng/ml) on Transwell inserts (0.4 mm) (Greiner) coated with fibronectin (7 mg/ml) and incubated for 72 hours. The medium in the upper compartment was replaced with SFM containing FITC-dextran and recombinant VEGF (50 ng/ml) (RELIATech GmbH). The amount of FITC-dextran that diffused through the endothelial monolayer into the lower compartment was measured. For the experiments using internalization inhibitors, the cells were preincubated for 1 hour with RAP (200 nM) (Calbiochem) or dynasore (20 mM) (Sigma) before VEGF treatment. For the siRNA experiments, HUVECs were transfected with uPAR or scramble siRNA (50 nM) using the Ca 3 (PO 4 ) 2 method. After 16 hours of transfection, the HUVECs were seeded in SFM containing bFGF (5 ng/ml) on Transwell inserts coated with fibronectin.
Surface biotinylation and immunoblotting
To analyze surface protein turnover, HUVECs in PBS were treated with thiolcleavable Sulfo-NHS-SS-Biotin (2 mg/ml) (Pierce) for 30 min on ice. Next, 4 ml of SFM containing VEGF (100 ng/ml) was added, and the cells were incubated at 37°C for 15 min. The cells were then incubated twice with 45 mM membrane-impermeable reducing agent GSH (Sigma) in 75 mM NaCl, 75 mM NaOH, and 1% bovine serum albumin (BSA) for 20 min. HUVECs were lysed on ice with lysis buffer [25 mM Hepes, 150 mM NaCl, 0.5% Triton X-100, 10% glycerol, and a cocktail of protease inhibitors (Roche)]. The biotinylated proteins were adsorbed onto streptavidincoated Sepharose beads for 2 hours at 4°C. The adsorbed proteins were eluted by boiling in reducing sample buffer. The proteins were analyzed by SDS-polyacrylamide gel electrophoresis (SDS-PAGE), followed by Western blotting.
Immunoprecipitation
A total of 1.5 × 10 6 cells were seeded in T75 flasks in 10 ml of SFM (Lonza) supplemented with bFGF (5 ng/ml) (Promega). After 48 hours, the HUVECs were incubated with VEGF (50 ng/ml) for 10 min at 37°C. After this treatment, the cells were incubated with a cross-linking agent (DTSSP, Thermo Scientific) for 2 hours at 4°C according to the manufacturer's protocol. The cells were lysed with 500 ml of lysis buffer. The HUVEC extracts were incubated overnight with mouse anti-uPAR (R&D Systems), goat anti-human VEGFR2 (R&D Systems), or a rabbit anti-b 1 integrin antibody (Millipore) (5 mg/ml) under rotation. Fifty microliters of protein A agarose was added and incubated for 1 hour at 4°C under rotation. After centrifugation for 2 min at 3000 rpm, the supernatants were discarded and the pellets were washed three times with the lysis buffer. After centrifugation, the immunoprecipitated proteins were eluted by boiling in reducing sample buffer. The proteins were analyzed by SDS-PAGE, followed by Western blotting.
Western blot analysis
Cells were lysed in lysis buffer and heated at 95°C for 10 min. Equal amounts of protein were resolved by 6 to 10% SDS-PAGE and transferred to polyvinylidene fluoride membranes according to the manufacturer's protocol. The blots were blocked for 1 hour at room temperature with 8% milk in tris-buffered saline with 0.1% Tween 20 and probed overnight at 4°C with 1:1000 mouse anti-uPAR (R&D Systems), rabbit anti-ERK1/2 (Millipore), rabbit anti-VEGFR2, rabbit anti-phospho-Tyr 1175 VEGFR2, rabbit anti-b 1 integrin, rabbit anti-phospho-ERK1/2 (Thr 202 /Tyr 204 ), rabbit anti-phospho-AKT, or rabbit anti-AKT (Cell Signaling). After three washes with tris-buffered saline containing 0.1% Tween 20, the appropriate secondary antibody at a 1:4000 dilution was added for 1 hour at room temperature. The bands were visualized by enhanced chemiluminescence with an ECL kit (Pierce). Quantification was performed with ImageJ software
Flow cytometry
After VEGF stimulation (50 ng/ml, 15 min), HUVECs were scraped off of the plates in PBS containing 5% BSA. After blocking in this solution, the appropriate primary antibody was added for 1 hour at 4°C to VEGFR2 (Cell Signaling), b 1 integrin (Millipore), b 3 integrin (Millipore), uPAR (R&D Systems), and LRP-1 (Calbiochem). Then, the appropriate FITCconjugated secondary antibody was added for 1 hour at 4°C. The cells were analyzed with a BD FACSCalibur flow cytometer.
In situ PLA
HUVECs were cultured in 35-mm petri dishes coated with gelatin. After incubation for 10 min with VEGF (50 ng/ml), the cells were washed with cold PBS, fixed with 4% paraformaldehyde for 15 min at 4°C, blocked, and incubated overnight with 1:100 mouse anti-uPAR (R&D Systems), rabbit anti-uPAR (American Diagnostica), rabbit anti-VEGFR2 (Cell Signaling), mouse anti-LRP-1 (Calbiochem), and mouse anti-b 1 integrin or anti-b 3 integrin (Millipore). The PLA was performed according to the manufacturer's instructions using the Duolink Detection Kit 563 (Olink Bioscience) with anti-mouse MINUS and anti-rabbit PLUS PLA probes. DAPI was used to stain the nuclei. The slides were analyzed by fluorescence microscopy (Nikon Eclipse 90i).
Retinal murine neovascularization model
Mice with an inactivation of the gene encoding uPAR (uPAR −/− ) and corresponding wild-type mice littermates used in this study have been previously described (74) . Mice are on a mixed C57BL/6 (75%) × 129 (25%) background. To analyze postnatal neovascularization in the mouse retina, uPAR −/− and wild-type pups were intraocularly injected at postnatal day 1 with VEGF (50 ng per eye) or vehicle and sacrificed at postnatal day 5. The eyes were fixed in 4% paraformaldehyde in PBS for 45 min, and the retinas were dissected, incubated with biotinylated isolectin B4 (Vector Laboratories), and stained with streptavidin-Alexa 488 (Invitrogen) before being flat-mounted as previously described (54) . The retinal radius (from the optic nerve to the edge of the retina) and the vascular radius (from the optic nerve to the vascular front) of each petal of the retina were measured. The value for each retina was calculated as the mean of the radii for all petals. The vascular coverage was calculated as the ratio between the vascular radius and the retinal radius. Four or five pups were used in each group. The animal experiment protocol was approved by the Institutional Ethics Committee of the University of Liège.
Matrigel plug assay
Matrigel plug implantation was performed as previously described (75) . Matrigel (BD Biosciences) was supplemented with fibroblast growth factor-2 (250 ng/ml), VEGF (300 ng/ml), and heparin (0.0025 U/ml). Matrigel (400 ml) was implanted subcutaneously into the right and left flanks of wild-type and uPAR −/− mice from either sex under anesthesia. After 10 days, the plugs were dissected from the mice and their weight was determined. Matrigels were ground in the presence of dispase solution. The concentration of hemoglobin in the supernatant was then determined directly by absorbance at 405 nm and compared with a standard curve of purified hemoglobin (Sigma). The animal experiment protocol used was approved by the Institutional Ethics Committee of the University of Liège.
Statistical analysis
Results were displayed graphically (bar diagrams) as mean and SE. For immunoprecipitation, Western blotting, and flow cytometry, normalized VEGF-treated values were tested for significance by the one-sample t test. For PLAs, control and VEGF-treated cells were compared by the Student's t test or the Mann-Whitney U test. When comparing several conditions, one-way analysis of variance (or the Kruskal-Wallis test) was applied followed by Dunn's post hoc multiple testing. When experiments were repeated under the same conditions (for example, for in vitro migration, proliferation and permeability assays, and in vivo experiments), data were treated by analysis of variance for factorial designs (general linear model) with fixed and random effects. All statistical analyses were carried out with Prism 5.0 (GraphPad Software) and STA-TISTICA 10 (StatSoft) software packages. Results were considered significant when P < 0.05; *P < 0.05, **P < 0.01, ***P < 0.001.
SUPPLEMENTARY MATERIALS
www.sciencesignaling.org/cgi/content/full/8/403/ra117/DC1 Fig. S1 . uPAR antibody or siRNA-mediated knockdown of uPAR prevents VEGF-induced migration.
